NCT07366840 2026-01-26
BRIGHT
Fudan University
Phase 2/3 Not yet recruiting
Clinical Trials
9 trialsNCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05426486 2024-10-30
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2/3 Active not recruiting
NCT05189067 2022-01-12
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT02581462 2020-08-11
PETRARCA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Completed
NCT00169104 2018-07-20
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Dartmouth-Hitchcock Medical Center
Phase 2/3 Terminated
NCT03085368 2017-07-28
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Peking Union Medical College Hospital
Phase 2/3 Unknown